医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Asahi Kasei Providing Samples of Hyaluronic Acid Nanogel as a New Pharmaceutical Excipient

2020年08月05日 AM11:00
このエントリーをはてなブックマークに追加


 

TOKYO

Asahi Kasei has established industrial manufacturing technology for hyaluronic acid (HA) nanogel* as a new pharmaceutical excipient, and is providing samples to prospective customers in order to commercialize the product.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200804005334/en/

Chemical structure and self-assembly of HA nanogel (Graphic: Business Wire)

Chemical structure and self-assembly of HA nanogel (Graphic: Business Wire)

The Functional Additives Division of Asahi Kasei’s Specialty Solutions SBU supplies Ceolus™ microcrystalline cellulose to pharmaceutical manufacturers around the world for use as an excipient for drug tablets. The commercialization of HA nanogel would expand the product lineup by adding a drug delivery system (DDS) base material for injection formulations.

HA nanogel is expected to improve the quality of life (QOL) for patients by enabling the low-toxicity solubilization of insoluble drugs, facilitating the formulation of biopharmaceuticals such as proteins and peptides by suppressing their aggregation and denaturation, and reducing the frequency of injection when repeated administration is required.

Characteristics of the new HA nanogel:

Structure
HA nanogel is derived by the partial modification of hyaluronic acid with cholesterol. In water, self-association occurs among the cholesterol portions due to hydrophobic interaction, causing the formation of nanometer-scale hydrogel. The physical properties of HA nanogel depend on the molecular weight of HA and the cholesterol modification rate. Two grades of samples, a dispersion grade and a precipitation grade, are currently available.

Functions
The hydrophobic interaction enables a wide variety of insoluble drugs, ranging from low and medium molecular weight (MW) compounds to proteins, to be enclosed in the nanogel by simple mixing. This makes HA nanogel suitable for use as a base material for DDS. The main functions are sustained release, solubilization, suppression of aggregation, and retention of drug activity. Grades can be optimized to match specific customer requirements.

Asahi Kasei will make a formal decision on the commercialization of HA nanogel after confirming that the provided samples have contributed to solutions for the development of drug formulations by customers.

Asahi Kasei remains committed to meeting the needs of customers through products that contribute to life and living for people around the world.

Inquiries regarding HA nanogel samples should be directed to:
New Product Development Office
Functional Additives Division
Specialty Solutions SBU
Asahi Kasei Corp.

hananogel@om.asahi-kasei.co.jp

* Asahi Kasei has an exclusive license for HA nanogel technology developed by Chugai Pharmaceutical Co., Ltd.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200804005334/en/

CONTACT

For more information, please contact:

Specialty Solutions SBU

Functional Additives Division

Yurika Tanaka

tanaka.yz@om.asahi-kasei.co.jp

Phone: +81-(0)3-6699-6863

Asahi Kasei Corp.

Corporate Communications

Phone: +81-(0)3-6699-3008

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 印尼生命科学与技术学院在NCRM NICHE 2021上赢得第16届Fujio Cup Quiz大赛;印度Rajalakshmi工程学院获得亚军
  • 辉凌将在ACG 2021上展示基于微生物群的在研活体生物治疗药物RBX2660用于治疗艰难梭菌反复感染和IBD患者的获奖真实临床转归分析
  • ShouTi Secures $100 Million Series B Financing to Accelerate Development of Life-Changing Medicines Fueled by Advanced Computational, Structure-Based Drug Design Platform
  • 硕迪B轮成功融资1亿美元,利用先进的计算和结构药物设计平台加速开发改变患者命运的药物
  • CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease